IRON
Disc Medicine, Inc.BS score 52.8MEDIUMPHASE3 · mkt cap $2.57B · rev ttm $0
drug hypothesis
DISC-3405 modulates Unknown - Not stated in filing to treat Polycythemia Vera (PV).
moa:Unknown - Not explicitly stated; trial measures hepcidin-25 and serum iron suggesting potential involvement in iron metabolism pathway
score breakdown
trial design70
base rate disconnect12
language red flags100
composite52.8
valuation analysis
market cap$2.57B
revenue ttm$0
phasePHASE3
historical base rate40%
disconnect ratio0.4x
lead trialNCT05745883
meta
cik0001816736
first discovered2026-04-09
last updated2026-04-10
statusACTIVE
llm model—
extracted at2026-04-10
trial design
Phase 2, open-label, non-randomized, single-arm study enrolling 60 participants with Polycythemia Vera. Primary endpoint is safety/tolerability. Key secondary endpoints include therapeutic response (absence of phlebotomy eligibility), proportion maintaining HCT <45%, and comprehensive PK parameters (AUC, Cmax, half-life, clearance).
primary endpoint:Number of participants with treatment-related adverse events as assessed by CTCAE (Up to 365 days)
claimed differentiation
Unknown - Not provided in filing data
language red flags
- Target not disclosed - biological target completely absent from filing data
- Mechanism of action not stated - must infer from hepcidin-25 measurements that iron metabolism may be involved
- No preclinical evidence provided
- No differentiation claims made - cannot assess competitive positioning
- No risk factors disclosed in filing
- Incomplete filing data - only clinical trial NCT06985147 provided without full SEC filing business section text
- Company identity not disclosed
upcoming catalysts
- 2025-08-12Trial start
- 2027-02Primary completion